# Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification (Ro-SjS)

> **NCT07414667** · — · NOT_YET_RECRUITING · sponsor: **Central Hospital, Nancy, France** · enrollment: 150 (estimated)

## Conditions studied

- Sjögren´s Syndrome

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07414667
- **Lead sponsor:** Central Hospital, Nancy, France
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07414667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07414667, "Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification (Ro-SjS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07414667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*